

Hermine I Brunner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2144796/hermine-i-brunner-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194 papers	8,160 citations	45 h-index	85 g-index
205 ext. papers	9,807 ext. citations	6.1 avg, IF	5.67 L-index

#	Paper	IF	Citations
194	Juvenile idiopathic arthritis.. <i>Nature Reviews Disease Primers</i> , 2022 , 8, 5	51.1	7
193	Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2022 , 48, 271-285	2.4	0
192	The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry.. <i>Frontiers in Medicine</i> , 2022 , 9, 842586	4.9	0
191	Tofacitinib for juvenile idiopathic arthritis - AuthorsSreply.. <i>Lancet, The</i> , 2022 , 399, 1866	4.0	0
190	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. <i>Lancet, The</i> , 2021 , 398, 1984-1996	4.0	13
189	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
188	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1264-1274	4.7	0
187	Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing. <i>Arthritis Care and Research</i> , 2021 , 73, 1379-1386	4.7	0
186	Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	5
185	International Consensus For The Dosing Of Corticosteroids In Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	3
184	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 336-346	9.5	7
183	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 852-858	4.1	4
182	Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. <i>Cytotherapy</i> , 2021 , 23, 37-45	4.8	1
181	Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 530-541	9.5	8
180	Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. <i>Arthritis Care and Research</i> , 2021 , 73, 580-585	4.7	9
179	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1073-1081	4.1	0
178	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 , 60, 4495-4507	3.9	3

177	Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus 2021 , 159-180		
176	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 , 60, 4568-4580	3.9	5
175	Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity. <i>Kidney International Reports</i> , 2021 , 6, 1949-1960	4.1	2
174	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1898-1909	9.5	7
173	Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. <i>RMD Open</i> , 2021 , 7,	5.9	1
172	Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis.. <i>Lupus</i> , 2021 , 9612033241062515		
171	Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis. <i>Arthritis Care and Research</i> , 2020 ,	4.7	3
170	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1945-1951	9.5	15
169	Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. <i>Pediatric Rheumatology</i> , 2020 , 18, 43	3.5	7
168	Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2020 , 22, 135	5.7	3
167	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. <i>Pediatric Rheumatology</i> , 2020 , 18, 19	3.5	8
166	The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. <i>Pediatric Rheumatology</i> , 2020 , 18, 7	3.5	15
165	Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. <i>Cell Reports Medicine</i> , 2020 , 1,	18	12
164	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. <i>Frontiers in Pharmacology</i> , 2020 , 11, 605060	5.6	3
163	Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. <i>Arthritis Care and Research</i> , 2020 , 72, 1636-1644	4.7	6
162	Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	8
161	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. <i>RMD Open</i> , 2020 , 6,	5.9	5
160	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2147-2158	9.5	13

159	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1340-1348	4.4	48
158	Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. <i>Paediatric Drugs</i> , 2020 , 22, 653-672	4.2	3
157	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2020 , 22, 211	5.7	2
156	Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. <i>Journal of Rheumatology</i> , 2020 , 47, 1506-1513	4.1	6
155	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. <i>Arthritis Care and Research</i> , 2020 , 72, 1420-1430	4.7	11
154	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 579-590	4.7	12
153	Proteomic profiling of urine: implications for lupus nephritis. <i>Expert Review of Proteomics</i> , 2019 , 16, 303-313	4.1	10
152	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 1117-1126	4.1	9
151	Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 251-259	5.3	11
150	Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment. <i>Pediatric Rheumatology</i> , 2019 , 17, 9	3.5	9
149	Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1943-1954	9.5	61
148	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019 , 46, 1006-1013	4.1	18
147	Elevated serum complement levels and higher gene copy number of complement are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE). <i>Lupus Science and Medicine</i> , 2019 , 6, e000333	4.6	8
146	Update on the treatment and outcome of systemic lupus erythematosus in children. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 464-470	5.3	12
145	Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. <i>Pediatric Nephrology</i> , 2019 , 34, 117-128	3.2	22
144	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019 , 71, 451-459	9.5	23
143	Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 162-170	4.4	5
142	Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity. <i>Rheumatology</i> , 2019 , 58, 321-330	3.9	12

141	Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1144-1154	9.5	33
140	American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 813-822	4.7	16
139	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018 , 27, 2392-2404	5.6	22
138	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1508-1518	9.5	17
137	Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 1621-1629	4.7	16
136	Brain gray matter volume differences in obese youth with type 2 diabetes: a pilot study. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2018 , 31, 261-268	1.6	6
135	Rash, Fever, and Pulmonary Hypertension in a 6-Year-Old Female. <i>Arthritis Care and Research</i> , 2018 , 70, 785-790	4.7	3
134	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018 , 38, 35-42	3.6	5
133	Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. <i>Journal of Pediatrics</i> , 2018 , 196, 22-30.e2	3.6	39
132	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 21-29	2.4	64
131	Environmental triggers in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 710-717	5.3	29
130	Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2018 , 16, 45	3.5	30
129	Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkinindex27 for use in childhood-onset systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018 , 5, e000275	4.6	5
128	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1710-1719	2.4	53
127	Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. <i>Pediatric Rheumatology</i> , 2018 , 16, 65	3.5	13
126	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. <i>Journal of Rheumatology</i> , 2018 , 45, 1173-1179	4.1	6
125	Validation of Patient-Reported Outcomes Measurement Information System Short Forms for Use in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017 , 69, 133-142	4.7	23
124	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 107-125	6.2	5

123	Altered Blood-Brain Barrier Permeability in Patients With Systemic Lupus Erythematosus: A Novel Imaging Approach. <i>Arthritis Care and Research</i> , 2017 , 69, 299-305	4.7	17
122	Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. <i>Arthritis Care and Research</i> , 2017 , 69, 1743-1750	4.7	12
121	Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults. <i>Journal of Rheumatology</i> , 2017 , 44, 1239-1248	4.1	25
120	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2017 , 184, 38-44	3.61	26
119	Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood. <i>Arthritis Care and Research</i> , 2017 , 69, 1449-1459	4.7	9
118	Effects of age and gender on reference levels of biomarkers comprising the pediatric Renal Activity Index for Lupus Nephritis (p-RAIL). <i>Pediatric Rheumatology</i> , 2017 , 15, 74	3.5	12
117	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. <i>Pediatric Rheumatology</i> , 2017 , 15, 86	3.5	41
116	Urine S100 proteins as potential biomarkers of lupus nephritis activity. <i>Arthritis Research and Therapy</i> , 2017 , 19, 242	5.7	31
115	Extrapolation or controlled trials in paediatrics: the current dilemma. <i>Archives of Disease in Childhood</i> , 2017 , 102, 949-951	2.2	8
114	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
113	Malignancy in Pediatric-onset Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2017 , 44, 1484-1486	4.86	7
112	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1884-1888	4.1	8
111	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. <i>Arthritis Research and Therapy</i> , 2017 , 19, 13	5.7	35
110	Advances in the care of children with lupus nephritis. <i>Pediatric Research</i> , 2017 , 81, 406-414	3.2	25
109	Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016 , 68, 195-202	4.7	17
108	Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016 , 68, 179-86	4.7	19
107	Mutations in the MTHFR gene are not associated with Methotrexate intolerance in patients with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2016 , 14, 11	3.5	12
106	Polyarticular Arthritis and Skin Nodulosis in a 14-Year-Old Female. <i>Arthritis Care and Research</i> , 2016 , 68, 700-5	4.7	1

105	Trial Design, Measurement, and Analysis of Clinical Investigations 2016 , 54-77.e2		1
104	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016 , 2, e000161	5.9	46
103	Relationship of cell-free urine MicroRNA with lupus nephritis in children. <i>Pediatric Rheumatology</i> , 2016 , 14, 4	3.5	13
102	Pain, Fatigue, and Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus. <i>Arthritis Care and Research</i> , 2016 , 68, 73-80	4.7	49
101	Tocilizumab for treating juvenile idiopathic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 559-664	6.4	13
100	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2016 , 55, 181-8	2.4	247
99	Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. <i>Arthritis Care and Research</i> , 2016 , 68, 1003-11	4.7	42
98	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016 , 68, 566-76	9.5	216
97	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. <i>Arthritis and Rheumatology</i> , 2016 , 68, 218-28	9.5	81
96	Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1377-85	9.5	28
95	Pharmacokinetic modeling of therapies for systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2015 , 8, 587-603	3.8	3
94	Half-life and safety of canakinumab in pediatric patients: comment on the article by Ilowite et Al. <i>Arthritis and Rheumatology</i> , 2015 , 67, 857-8	9.5	1
93	Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 1119-27	4.7	15
92	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , 2015 , 67, 891-7	4.7	268
91	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1110-7	2.4	195
90	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. <i>Journal of Rheumatology</i> , 2015 , 42, 2419-26	4.1	28
89	Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. <i>Arthritis and Rheumatology</i> , 2015 , 67, 840-8	9.5	52
88	Biomarkers for childhood-onset systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2015 , 17, 471	4.9	16

87	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. <i>Arthritis and Rheumatology</i> , 2014 , 66, S8-S9	9.5	6
86	A52: The Impact of Adalimumab on Growth in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, S77-S78	9.5	1
85	Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 557-566	2.4	54
84	Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children. <i>Lupus Science and Medicine</i> , 2014 , 1, e000038	4.6	12
83	A33: Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2014 , 66, S51-S52	9.5	
82	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014 , 66, S5-S6	9.5	4
81	Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. <i>Pediatric Rheumatology</i> , 2014 , 12, 29	3.5	21
80	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 401-6	2.4	21
79	Value of questionnaire-based screening as a proxy for neurocognitive testing in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2014 , 66, 943-8	4.7	10
78	Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. <i>Journal of Rheumatology</i> , 2014 , 41, 1163-70	4.1	48
77	A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. <i>Arthritis and Rheumatology</i> , 2014 , 66, S222-S223	9.5	
76	Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2459-65	4.1	26
75	A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry. <i>Arthritis and Rheumatology</i> , 2014 , 66, S86-S87	9.5	3
74	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. <i>Arthritis and Rheumatology</i> , 2014 , 66, S96-S97	9.5	1
73	A22: Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis: Status of Use in Daily Clinical Care. <i>Arthritis and Rheumatology</i> , 2014 , 66, S35-S36	9.5	1
72	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, S23-S24	9.5	3
71	Determinants of health-related quality of life in children newly diagnosed with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 263-9	4.7	36
70	Functional neuronal network activity differs with cognitive dysfunction in childhood-onset systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013 , 15, R40	5.7	18

69	Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013 , 15, 218	5.7	81
68	Biomarkers and updates on pediatrics lupus nephritis. <i>Rheumatic Disease Clinics of North America</i> , 2013 , 39, 833-53	2.4	28
67	International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 1416-23	4.7	44
66	Brain morphometric changes associated with childhood-onset systemic lupus erythematosus and neurocognitive deficit. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2190-200		18
65	Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 372-81	4.7	26
64	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 727-40	3.8	32
63	Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012 , 64, 375-83	4.7	131
62	Taxonomy for systemic lupus erythematosus with onset before adulthood. <i>Arthritis Care and Research</i> , 2012 , 64, 1787-93	4.7	109
61	Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. <i>New England Journal of Medicine</i> , 2012 , 367, 2396-406	59.2	484
60	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. <i>New England Journal of Medicine</i> , 2012 , 367, 2385-95	59.2	577
59	Inactive disease and remission in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012 , 64, 683-93	4.7	29
58	Academic outcomes in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012 , 64, 1167-74	4.7	22
57	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2012-21		202
56	Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2687-97		113
55	Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 174-9	4.1	88
54	Pediatric SLE--towards a comprehensive management plan. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 225-33	3.1	45
53	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 1-24	6.2	41
52	Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. <i>Arthritis Research and Therapy</i> , 2011 , 13, R199	5.7	39

51	TRIAL DESIGN, MEASUREMENT, AND ANALYSIS OF CLINICAL INVESTIGATIONS 2011 , 127-156		2
50	SLE in Children 2011 , 573-597		
49	Neuroinflammation and Pediatric Lupus 2011 , 423-437		
48	Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 40, 307-13	5.3	45
47	Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. <i>Clinical Therapeutics</i> , 2011 , 33, 1524-36	3.5	10
46	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011 , 63, 1213-23	4.7	25
45	Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study. <i>Journal of Rheumatology</i> , 2011 , 38, 1020-5	4.1	16
44	Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 658-62	3.2	12
43	Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. <i>Rheumatic Disease Clinics of North America</i> , 2010 , 36, 53-80, vii-viii	2.4	176
42	Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 335-44	4.7	14
41	Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 811-20	4.7	21
40	A proposed framework to standardize the neurocognitive assessment of patients with pediatric systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 1029-33	4.7	24
39	Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010 , 62, 950-9	4.7	28
38	Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3131-9		43
37	Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 1536-45	4.1	47
36	Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. <i>Pediatric Research</i> , 2009 , 65, 530-6	3.2	94
35	Developing outcome measures for paediatric rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 609-24	5.3	35
34	Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1496-507		109

33	Disease control and health-related quality of life in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 393-9		62
32	Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2772-81		108
31	The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents. <i>Current Rheumatology Reports</i> , 2009 , 11, 212-7	4.9	8
30	Biomarkers for renal disease in childhood. <i>Current Rheumatology Reports</i> , 2009 , 11, 218-25	4.9	15
29	Adherence to medications in systemic lupus erythematosus. <i>Journal of Clinical Rheumatology</i> , 2008 , 14, 195-201	1.1	73
28	Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. <i>Pediatric Nephrology</i> , 2008 , 23, 403-12	3.2	104
27	Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008 , 58, 556-62		354
26	Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. <i>Arthritis and Rheumatism</i> , 2007 , 57, 1000-6		75
25	Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 57, 1174-82		54
24	Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4151-63		57
23	Pain, Fatigue, Family Functioning, and Attitude Toward Illness in Children with Juvenile Rheumatic Diseases. <i>Journal of Developmental and Physical Disabilities</i> , 2007 , 19, 135-144	1.5	18
22	School Support and Functioning for Children with Juvenile Rheumatic Diseases. <i>Journal of Developmental and Physical Disabilities</i> , 2007 , 19, 81-89	1.5	5
21	Identification of a urinary proteomic signature for lupus nephritis in children. <i>Pediatric Nephrology</i> , 2007 , 22, 2047-57	3.2	59
20	Cost of treatment of childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 55, 184-8		29
19	Differences in disease outcomes between medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 55, 378-84		38
18	Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2577-84		185
17	Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus. <i>Journal of Pediatrics</i> , 2006 , 148, 571-3	3.6	13
16	Specialized Neuromuscular Training to Improve Neuromuscular Function and Biomechanics in a Patient With Quiescent Juvenile Rheumatoid Arthritis. <i>Physical Therapy</i> , 2005 , 85, 791-802	3.3	35

15	Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. <i>Journal of Clinical Rheumatology</i> , 2005 , 11, 194-204	1.1	39
14	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2607-15		121
13	Minimal clinically important differences of the childhood health assessment questionnaire. <i>Journal of Rheumatology</i> , 2005 , 32, 150-61	4.1	39
12	International consensus on preliminary definitions of improvement in adult and juvenile myositis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 2281-90		173
11	Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. <i>Arthritis and Rheumatism</i> , 2004 , 51, 763-73		81
10	Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 51, 899-908		11
9	Health-related quality of life in children with rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 602-12	5.3	48
8	European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 49, 335-41		45
7	Item weightings for the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index using Rasch analysis do not lead to an important improvement. <i>Journal of Rheumatology</i> , 2003 , 30, 292-7	4.1	15
6	Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. <i>Arthritis and Rheumatism</i> , 2002 , 46, 436-44		235
5	Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. <i>Journal of Rheumatology</i> , 2002 , 29, 490-501	4.1	22
4	Preliminary definition of disease flare in juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 1058-64	4.1	81
3	Current medication choices in juvenile rheumatoid arthritis II--update of a survey performed in 1993. <i>Journal of Clinical Rheumatology</i> , 2001 , 7, 295-300	1.1	18
2	Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1354-60		154
1	Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2346-55		69